Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104812 · ClinicalTrials.gov registry record · Phase 2
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
A Phase 2 study of Mild Autonomous Cortisol Secretion and Autonomous Cortisol Secretion (ACS), sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07104812: Recruiting Phase 2 study of Mild Autonomous Cortisol Secretion and Autonomous Cortisol Secretion (ACS), sponsored by Mayo Clinic.
NCT07104812 is a Phase 2 study of Mild Autonomous Cortisol Secretion and Autonomous Cortisol Secretion (ACS) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104812, a Phase 2 study of Mild Autonomous Cortisol Secretion and Autonomous Cortisol Secretion (ACS), is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
Primary Outcome
Number of adverse events
Conditions Studied
Interventions
- DRUG Osilodrostat 1 MG
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07104812 shows while recruiting
NCT07104812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Mild Autonomous Cortisol Secretion appearing as the primary indexed condition, and to 1 intervention - of which Osilodrostat 1 MG is the first listed.
NCT07104812 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07104812 about?
NCT07104812 is a clinical study titled "Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)". The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
What is the current status of trial NCT07104812?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-01-14. Estimated completion is 2027-01.
What conditions does trial NCT07104812 study?
This clinical trial studies the following conditions: Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS).
What interventions are being tested in trial NCT07104812?
The interventions under investigation include: Osilodrostat 1 MG (DRUG).
Who is sponsoring clinical trial NCT07104812?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104812 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07104812's enrollment target sits among peer trials
15 1920th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI